RxDoctor Payments Data

Christopher McCourt

Family · Wooster, OHNPI 1376994475

Payments from drug & device makers

$8,961in general payments, 2019–2025

Across 326 payments — averaging $27.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$3K
  • AbbVie$1K
  • Otsuka America Pharmaceutical, Inc.$980
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$696
  • Lundbeck LLC$639
  • E.r. Squibb & Sons, L.L.C.$419
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$6,38399%
  • Education$771%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,961 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$26,272
Medicare patients
23
Services billed
279

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CaplytaLumateperone Tosylate31$53,889
VraylarCariprazine Hcl26$40,119
RexultiBrexpiprazole17$27,071
AuvelityDextromethorphan Hbr/Bupropion23$23,533
LybalviOlanzapine/Samidorphan Malate14$21,138
TrintellixVortioxetine Hydrobromide14$8,053
Lurasidone Hcl34$5,417
Aripiprazole34$1,964
Desvenlafaxine Succinate ErDesvenlafaxine Succinate20$1,107
Quetiapine Fumarate35$1,055
Lamotrigine91$970
Trazodone Hcl85$961
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine12$880
Vilazodone Hcl15$812
Olanzapine33$760

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$696$53,88931 claims
AbbVieVraylar$1,158$40,11926 claims
Otsuka America Pharmaceutical, Inc.Rexulti$980$27,07117 claims
Axsome Therapeutics, Inc.Auvelity$357$23,53323 claims
Alkermes, Inc.Lybalvi$2,843$21,13814 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$202$8,05314 claims
Almatica Pharma LLCSertraline Hcl$20$28127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.

Other family in Wooster

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →